Competing interests
ONCOLOGY, FOUNDER, BREAST, GLIOBLASTOMA MULTIFORME
The authors declare the following competing interests. J.S.P.: equity and consulting from Reveal Genomics; royalties from patent from Veracyte. B.S.: participation in speaker’s Bureau for AstraZeneca. E.P.W.: honoraria and equity, board member for Oncoclinicas; consultant honoraria from Carrick Therapeutics, GSK, Jounce Therapeutics; Consultant/Honoraria Research to Institute from Genentech/Roche; honoraria from Genomic Health; scientific advisory board honoraria from Leap Therapeutics. S.E.-A.: grant from Novartis within the submitted work and from Roche/Genentech and Pfizer outside the submitted work. M.P.: invited speaker for AstraZeneca, Lilly, MSD, Novartis, Pfizer, Roche-Genentech; consultant for Camel-IDS/Precirix, Roche-Genentech; advisory board for Frame Therapeutics, Gilead, Immunomedics, Immutep, Menarini, NBE Therapeutics, Odonate, Roche-Genentech, SeaGen, Seattle Genetics; member of boards of directors, scientific board for Oncolytics; research grants to her Institution from AstraZeneca, Immunomedics, Lilly; funding to her Institution from Menarini, MSD, Novartis, Pfizer, Radius, Roche-Genentech, Servier, Synthon. S.DC.: fees for medical education from Novartis, Pierre-Fabre, and IQVIA; institutional grant IG 20774 of Fondazione Associazione Italiana Ricerca contro il Cancro (AIRC); “ad hoc” medical advisor for Medica Scientia Innovation Research (MEDSIR), Barcelona (Spain). W.F.S.: founder stock in Delphi Diagnostics and publicly traded stock in IONIS Pharmaceuticals and Eiger BioPharmaceuticals; consultant/advisor to Merck, AstraZeneca; co-inventor of pending patent “Targeted Measure of Transcriptional Activity Related to Hormone Receptors”, United States, Provisional Patent Application Serial No. 62/329,774; support for unrelated research from Pfizer; uncompensated scientific advisor to Delphi Diagnostics. I.E.K.: advisory board participation/consultant and received honoraria from Bristol Meyers Squibb, Daiichi/Sankyo, Macrogenics, Genentech/Roche, Seagen, AstraZeneca, Novartis, Merck; institutional research funding/grants (paid to Institution) from Genentech/Roche, Pfizer, Macrogenics. S.L.: research funding to her institution from Novartis, Bristol Meyers Squibb, Merck, Puma Biotechnology, Eli Lilly, Nektar Therapeutics, AstraZeneca, Roche-Genentech and Seattle Genetics; consultant (not compensated) to Seattle Genetics, Novartis, Bristol Meyers Squibb, Merck, AstraZeneca, Eli Lilly, Pfizer, Gilead Therapeutics and Roche-Genentech; consultant (paid to her institution) to Aduro Biotech, Novartis, GlaxoSmithKline, Roche-Genentech, AstraZeneca, Silverback Therapeutics, G1 Therapeutics, PUMA Biotechnologies, Pfizer, Gilead Therapeutics, Seattle Genetics, Daiichi Sankyo, Merck, Amunix, Tallac Therapeutics, Eli Lilly and Bristol Meyers Squibb. L.P.: consulting fees and honoraria from Seagen, Pfizer, AstraZeneca, Merck, Novartis, Bristol-Myers Squibb, Pfizer, Genentech, Eisai, Pieris, Immunomedics, Clovis, Syndax, H3Bio, Radius Health, Personalis, Daiichi, Natera and institutional research funding from Seagen, AstraZeneca, Merck, Pfizer and Bristol Myers Squibb. R.S.: non-financial support from Merck and Bristol Myers Squibb (BMS); research support from Merck, Puma Biotechnology and Roche; personal fees from Roche, BMS and Exact Sciences for advisory boards. C.M.P.: equity stock holder and consultant of BioClassifier LLC; listed as an inventor on patent applications for the Breast PAM50 Subtyping assay; equity stock holder and consultant of Reveal Genomics. L.A.C.: research funding to her Institution from Sindax, Novartis, NanoString Technologies, Seattle Genetics, Veracyte, AstraZeneca; Royalty-sharing agreement, investorship interest in licensed intellectual property to startup company, Falcon Therapeutics, that is designing neural stem cell–based therapy for glioblastoma multiforme (immediate family member); uncompensated relationship for Eisai, Sanofi, Lilly, SeaGen, Novartis (Institution), G1 Therapeutics (Institution), Genentech/Roche (Institution), GlaxoSmithKline (Institution), AstraZeneca (Institution), Daiichi Sanyo (Institution), Exact Sciences (Institution). C.S.: advisory board (receipt of honoraria or consultations fees) for Astellas, Cepheid, Vertex, Seattle genetics, Puma, Amgen, Exact Sciences; participation in company sponsored speaker’s bureau for Eisai, Prime Oncology, Teva, Foundation Medicine, Exact Sciences; other support (travel, accommodation expenses) from Roche, Genentech, Pfizer. The remaining authors declare no non-financial or financial competing interests.